RIPK1 and Stroke: Given the high knockdown efficiency of Ripk1 and Nsf in vivo after tMCAO, we subsequently determined the therapeutic potential of Ripk1 and Nsf knockdown on stroke outcome through injecting wild-type mice with AAV-EF1α-CasRx-Ripk1-Nsf (containing gRNA 8 for Ripk1 and gRNA 9 for Nsf) into the S1BF and striatum 14 days prior to tMCAO/sham operation (Figure 1A), along with AAV-EF1α-mCherry, which served as a fluorescent marker indicating the infected area of the virus (Figure 1B).